Osteoarthritis (OA)
Osteoarthritis (OA) is one of the most common arthritis-related chronic disorders
characterized by articular cartilage degeneration, thickening of subchondral bone, and
osteophyte formation. Disability of chondrocytes to produce sufficient functional matrix in
order to repair damaged matrix is one of the prominent features of osteoarthritis.
Most conventional treatments for OA such as physical therapy, drug therapy, and surgery
are essential to manage the pain, stiffness, and swelling but are not effective to prevent the
OA progression.
The results of investigations have demonstrated that Mesenchymal Stem Cell (MSC)-based
therapy encourages pain reduction and OA improvement mostly due to the differentiation
capability of MSCs.
It is demonstrated that both TGF-β1 and insulin-like growth factor 1
(IGF-1) act synergistically to stimulate MSCs’ chondrogenic differentiation.
MSCs from human umbilical cord blood (UCB) compared to Adipose-MSCs and Bone
Marrow-MSCs have many advantages such as higher proliferation rates, greater expansion
ability, higher purity, abundant supply, and inexhaustibility for therapy.
Stem Cell Res Ther. 2020; 11: 492.
To Learn More :
